| Bioactivity | MS8709 (10), a potential anticancer therapeutic, is a first-in-class G9a/GLP PROTAC degrader. MS8709 (10) is based on G9a/GLP inhibitor UNC0642 and recruits the von Hippel Lindau (VHL) E3 ligase[1]. |
| Invitro | MS8709 (10) 在0.3和3 µM的浓度下都能显著降解G9a和GLP。特别地，具有11个碳原子链接器的化合物10在0.3 µM浓度下诱导了G9a约70%和GLP约50%的降解，而在3 µM浓度下诱导了两种蛋白质的完全降解[1].MS8709 (10，1 μM，24 h) 通过依赖VHL和UPS的方式诱导G9a/GLP降解[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> MS8709 相关抗体: |
| Formula | C64H95F2N11O7S |
| Molar Mass | 1200.57 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Julia Velez, et al. Discovery of the First-in-class G9a/GLP PROTAC Degrader. BioRxiv. Posted February 29, 2024. |